CPMG Inc’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-2,896,901
| Closed | -$295M | – | 4 |
|
|
2023
Q2 | $295M | Hold |
2,896,901
| – | – | 59.26% | 1 |
|
|
2023
Q1 | $263M | Hold |
2,896,901
| – | – | 53.13% | 1 |
|
|
2022
Q4 | $110M | Hold |
2,896,901
| – | – | 27.63% | 2 |
|
|
2022
Q3 | $72.8M | Hold |
2,896,901
| – | – | 14.28% | 2 |
|
|
2022
Q2 | $88M | Hold |
2,896,901
| – | – | 17.69% | 2 |
|
|
2022
Q1 | $94.9M | Hold |
2,896,901
| – | – | 15.92% | 2 |
|
|
2021
Q4 | $76.4M | Hold |
2,896,901
| – | – | 14.09% | 3 |
|
|
2021
Q3 | $291M | Hold |
2,896,901
| – | – | 32.14% | 2 |
|
|
2021
Q2 | $410M | Hold |
2,896,901
| – | – | 67.78% | 1 |
|
|
2021
Q1 | $289M | Hold |
2,896,901
| – | – | 55.24% | 1 |
|
|
2020
Q4 | $358M | Sell |
2,896,901
-166,666
| -5% | -$21.9M | 55.16% | 1 |
|
|
2020
Q3 | $298M | Hold |
3,063,567
| – | – | 49.63% | 1 |
|
|
2020
Q2 | $478M | Hold |
3,063,567
| – | – | 63.81% | 1 |
|
|
2020
Q1 | $442M | Hold |
3,063,567
| – | – | 76.81% | 1 |
|
|
2019
Q4 | $626M | Buy |
3,063,567
+40,218
| +1% | +$7.34M | 47.15% | 1 |
|
|
2019
Q3 | $243M | Hold |
3,023,349
| – | – | 27.14% | 2 |
|
|
2019
Q2 | $285M | Hold |
3,023,349
| – | – | 33.71% | 2 |
|
|
2019
Q1 | $258M | Hold |
3,023,349
| – | – | 30.83% | 2 |
|
|
2018
Q4 | $170M | Buy |
3,023,349
+110,826
| +4% | +$6.77M | 15% | 2 |
|
|
2018
Q3 | $238M | Hold |
2,912,523
| – | – | 16.57% | 2 |
|
|
2018
Q2 | $102M | Hold |
2,912,523
| – | – | 9.64% | 2 |
|
|
2018
Q1 | $59.7M | Hold |
2,912,523
| – | – | 6.68% | 4 |
|
|
2017
Q4 | $82.5M | Buy |
+2,912,523
| New | +$81.3M | 8.34% | 3 |
|
Other funds holding RETA
CPMG Inc's RETA Position: Q3 2023 in Review
CPMG Inc sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 2,896,901 shares — an estimated $295M sold.
CPMG Inc first reported a position in RETA in Q4 2017 and held it in 23 quarters. The position peaked at $626M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- CPMG Inc reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- CPMG Inc sold 2,896,901 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $295M.
- CPMG Inc first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2017 and held it in 23 quarters.
- CPMG Inc's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $626M in Q4 2019.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on CPMG Inc's 13F filing for Q3 2023, filed 14 Nov 2023.